AI software receives FDA 510(k) clearance
Bracco and Avicenna.AI have received FDA 510(k) clearance for UPTUNITY™ | Aneurysm, an AI software designed to support brain aneurysm detection and assessment on CTA images. The software is the first product in Bracco’s new UPTUNITY™ portfolio of AI-enabled clinical decision support solutions.
The technology integrates AI assistance into radiologists’ existing reading workflows. It is intended to support medical specialists in identifying suspected aneurysms and assessing changes over time, while leaving clinical decision-making to the physician.
Detection and longitudinal follow-up
UPTUNITY | Aneurysm combines computer-assisted detection (CADe) and diagnosis (CADx) with follow-up functionality (MIMPS). The detection software identifies suspected saccular brain aneurysms greater than 3 mm on head CTA images and provides information about their presence, location, and size to support assessment and characterization.
For patients with known aneurysms, the follow-up functionality provides quantitative measurements and comparisons between examinations to assess changes over time. The integrated workflow therefore covers both initial identification and subsequent monitoring.
The software is intended for use as a concurrent reading aid by appropriately trained medical specialists. Its output is designed to be considered alongside the CTA images. It is not intended to replace a full patient evaluation or a qualified physician’s review, nor should it be used as the sole basis for making or confirming a diagnosis.
Expansion of Bracco’s AI portfolio
The launch expands Bracco’s Digital Health strategy into interpretive AI and complements its existing AI offerings. These include AiMIFY®, developed in collaboration with Subtle Medical, which applies AI to amplify existing contrast enhancement in brain MRI for improved lesion visualization.
Source: Bracco










